Ensysce Biosciences, Inc. (ticker: ENSC) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of ENSC's SEC filings surfaces 3 active risk signals, including 2 auditor-change signals, and 1 late-filing signal. ENSC reported $5.07M in revenue and -$19.05M for the period ending 2025-12-31, with operating cash flow of -$7.81M. Cash and equivalents stood at $4.31M (up 23.1% year-over-year). Total assets of $7.45M exceed total liabilities of $4.57M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
ENSC Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Ensysce Biosciences, Inc. (ENSC) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.